Skip NavigationSkip to Content
Return Return to Search Results

Combination Treatment With Sorafenib and Everolimus Regresses a Doxorubicin-resistant Osteosarcoma in a PDOX Mouse Model

  1. Author:
    Higuchi, Takashi
    Sugisawa, Norihiko
    Miyake, Kentaro
    Oshiro, Hiromichi
    Yamamoto, Norio
    Hayashi, Katsuhiro
    Kimura, Hiroaki
    Miwa, Shinji
    Igarashi, Kentaro
    Kline,Zoey
    Belt,Paige
    Chawla, Sant P
    Bouvet, Michael
    Singh,Shree Ram
    Tsuchiya, Hiroyuki
    Hoffman, Robert M

  2. Author Address

    AntiCancer, Inc., San Diego, CA, U.S.A., Department of Surgery, University of California, San Diego, CA, U.S.A., Department of Orthopedic Surgery, Kanazawa University, Kanazawa, Japan., Basic Research Laboratory, National Cancer Institute, Frederick, MD, U.S.A., Sarcoma Oncology Center, Santa Monica, CA, U.S.A., Basic Research Laboratory, National Cancer Institute, Frederick, MD, U.S.A. all@anticancer.com singhshr@mail.nih.gov tsuchi@med.kanazawa-u.ac.jp., Department of Orthopedic Surgery, Kanazawa University, Kanazawa, Japan all@anticancer.com singhshr@mail.nih.gov tsuchi@med.kanazawa-u.ac.jp., AntiCancer, Inc., San Diego, CA, U.S.A. all@anticancer.com singhshr@mail.nih.gov tsuchi@med.kanazawa-u.ac.jp.,
    1. Year: 2019
    2. Date: Sep
  2. Journal: Anticancer research
    1. 39
    2. 9
    3. Pages: 4781-4786
  4. Type of Article: Article
  5. ISSN: 0250-7005
  1. Abstract:

    Osteosarcoma is a rare but recalcitrant type of bone cancer. To discover an effective therapy for osteosarcoma, we used a patient-derived orthotopic xenograft (PDOX) mouse model. A PDOX mouse model has been established for all major cancer types. Strong synergistic efficacy of sorafenib (SFN) and everolimus (EVL) has been demonstrated in several cancers. In the present study, we examined the efficacy of a SFN and EVL combination on a doxorubicin (DOX)-resistant osteosarcoma PDOX. The osteosarcoma PDOX models were randomly divided into five treatment groups, each containing six mice: Control; DOX; SFN; EVL; and a combination of SFN and EVL. Mice were treated for 14 days. To observe the efficacy of these treatments, tumor size and body weight were measured, and histological sections were analyzed. Tumor growth regression was observed only in the mice treated with the combination of SFN-EVL. Histological analysis revealed necrosis with degenerative changes in tumors treated with a combination of SFN-EVL. A SFN-EVL combination could be a novel effective treatment option for osteosarcoma. Copyright© 2019, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

    See More

  1. Keywords:

External Sources

  1. View Full Text
  2. DOI: 10.21873/anticanres.13662
  3. PMID: 31519579
  4. View record in Web of Science®
  5. WOS: 000486457600025
  6. PII : 39/9/4781

Library Notes

  1. Fiscal Year: FY2019-2020
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel